The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
about
Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.The current state of adverse event reporting in hemophilia.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Safety surveillance in haemophilia and allied disorders.Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.Haemophilia in a real-world setting: the value of clinical experience in data collection.Emerging therapies for hemophilia: controversies and unanswered questions.European principles of inhibitor management in patients with haemophilia.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.Practical aspects of extended half-life products for the treatment of haemophilia
P2860
Q30234910-6D320E5C-1A6B-4A43-BA4B-D6CE8C0223D3Q30239952-CC8AC72C-B810-42AE-A9E8-E31288C448DAQ35565320-51BE1D4A-2200-4F6D-81DD-D808335DD3E7Q38784133-A3317D92-C039-4951-A3A6-FAC8AC280ED4Q38841025-5F8B6350-7692-4D58-AC9B-BA9BBB1D0CB9Q38958322-0F1A3BF5-8DCC-4EBD-9B2F-E9811282CEF5Q39666092-36D1F365-5D0F-4075-B56F-FB9269ABCC15Q45855101-054269E9-2690-4B93-AA8C-1AA5B794E17AQ45875555-2A9D7537-E6B6-4224-87DD-DC583E14EEEAQ45882636-D679EDDE-D9A7-4C13-B4EE-364A61C166E4Q54958581-B1B9A5DE-CEF0-4E91-8D03-3B8FDBF38AECQ54981504-B35873A9-5F65-41CA-A0E8-33F8C2C0C1A2Q55313906-D839012D-1CFB-431D-81F8-4A6C643DCEC9Q58761664-35208E39-B49C-4968-A8E0-CA65E6A6605A
P2860
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The incidence of factor VIII i ...... prospective cohort comparison.
@en
The incidence of factor VIII i ...... prospective cohort comparison.
@nl
type
label
The incidence of factor VIII i ...... prospective cohort comparison.
@en
The incidence of factor VIII i ...... prospective cohort comparison.
@nl
prefLabel
The incidence of factor VIII i ...... prospective cohort comparison.
@en
The incidence of factor VIII i ...... prospective cohort comparison.
@nl
P2093
P2860
P921
P356
P1433
P1476
The incidence of factor VIII i ...... prospective cohort comparison.
@en
P2093
B P Palmer
E A Chalmers
M Williams
P W Collins
S Rangarajan
P2860
P304
P356
10.1111/HAE.12563
P577
2014-11-07T00:00:00Z